A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors

This study is the first-in-human Phase I study of SYS6040 for injection, comprising two phases: Dose escalation with backfill (Phase Ia) and cohort expansion (Phase Ib).The planned study population consists of subjects with advanced solid tumors.The objective is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SYS6040 for injection as monotherapy in participants with advanced solid tumors.

Trial Details

NCT ID
NCT06970795
Phase
PHASE1
Sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SYS6040 for injection
Locations (sample)
  • Changchuan, Jilin, China|41.74545,127.03365

Key Eligibility Criteria

  • 1）Aged ≥18 years; 2) Subjects with histologically or cytologically confirmed advanced solid tumors who have failed standard therapy, are intolerant…
  • 3\) At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST v1.1); 4) ECOG score of 0 or 1; 5) Life expectancy ≥3 m…
  • Neutrophil count ≥1.5×109/L;
  • Platelet count ≥100×109/L;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →